Truist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and lowers the price target from $87 to $85.
Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and lowers the price target from $87 to $85.